Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 6/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337536 | 0.91 | KDR (0.42) | KDRBRAFMETRAF1MAPK3 | |
| SCHEMBL4337547 | 0.81 | RAF1 (0.47) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL13860912 | 0.80 | KDR (0.47) | KDRMETRAF1MAPK3HSPB1 | |
| SCHEMBL4323202 | 0.80 | GSK3B (0.44) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL4334131 | 0.79 | KDR (0.41) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL2259653 | 0.79 | RAF1 (0.50) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL4327004 | 0.78 | KDR (0.42) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL13861222 | 0.78 | KDR (0.42) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL4321307 | 0.78 | KDR (0.42) | KDRBRAFRAF1MAPK3HSPB1 | |
| SCHEMBL13861244 | 0.77 | KDR (0.43) | KDRBRAFRAF1MAPK3HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | KDR 7/4885BRAF 68/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.